CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

bluebird bio

Scott Cleve, Vice President Regulatory Operations and Compliance

How to Manage Regulatory Compliance

Scott Cleve

Scott Cleve

Data will continue to disrupt Regulatory processes and systems.  There are several factors that drive this disruption such as granular data requirements from health authorities, financial pressure to do more with less, and organizational pressure to improve efficiency and quality. From compliance activities to process improvements, companies will need to unify their data to meet these demands.


This should not be a surprise since the data and information that sponsor companies share with health authorities has become increasingly granular over the past 20 years. Initiatives like Structure Product Labeling(SPL),electronic Common Technical Document (eCTD),Study Data Tabulation Model(SDTM),Extended Medicinal Product Dictionary(xEVMPD),and Identification of Medicinal Products(IDMP)are examples of standards, guidance and regulations that drive the capture and exchange of structured drug and biologic data. These standards prompted the creation of databases, systems, and tools to store and submit data in a compliant manner to support narrative information delivered in documents.


Now is the time for companies to consider data unification. Data unification is the process of turning data from multiple sources into a unified set of records that can be trusted and relied upon in every process, system, or service in use.


Companies that embrace and prioritize unifying their data can meet compliance requirements and utilize trusted, curated data to unlock digital technology to improve processes and systems.

 


Seeing this you would think that there is a complete set of processes, systems, and standards for data intake, curation, storage, and transmission between sponsors, third party vendors and health authorities. Unfortunately, the truth is that there is still a long way to go. Information provided to health authorities (and internally at sponsor companies) is still primarily captured in documents – often in PDF format. Data sits in separate systems without common data definitions or governance models.  Data is duplicated from system to system due the lack of a data model or interfaces between systems and databases. The lack of data governance and data sharing leads to companies spending time and resources on quality checks and validation (and re-validation) of data.


You may ask “How did we get here?” In many cases companies did not implement systems and databases with the end in mind. Additionally, companies did not (or could not) know about each new system or piece of data that would eventually be needed. 


Or companies just relied on vendor solutions to solve a specific business case without considering the larger context of how the data in a solution fit into the overall architecture (for systems and data).


Defining and identifying master data in our organizations is one aspect of data unification. When master data is applied across an organization, the data is captured and verified once in the source system and then referenced in other databases, systems, processes, etc.  This results in one source for data input and any changes to data in the source are reflected in the referencing databases, systems, and processes. Another benefit is the elimination of redundant quality checks and revalidation of data since it was input and verified at the source.


A potential pitfall of data unification or a data governance program within an organization is that it becomes siloed in the same manner that our systems are siloed today.  This needs to be avoided.  An example is when data governance is implemented at a functional or departmental level versus at an organizational level. Unfortunately, this will only create a larger departmental silo that includes data governance and systems.  While it’s true that quick wins can occur at the functional level, if data are not connected organizationally, we will not achieve data unification.


Organizations need to treat data as an asset and not an afterthought and invest in the people, processes, and systems to unlock the benefits of unified data. Achieving a unified data framework requires a corporate mandate, prioritization, and funding to establish data governance, master data (and data) mapping, and standards across the organization. Cross-functional data governance bodies need to be empowered to be stewards for the data unification framework and enforce data reviews for new systems, upgrades, and changes.


Having unified data will allow companies to comply with increasingly granular data requirements from health authorities.  A unified data model will reduce redundant activities that occur today by eliminating the need to duplicate data from system to system and eliminate the need for quality checks since the data is verified in the source system. Unified data also opens opportunities to use digital tools like Artificial Intelligence (AI), Machine Learning (ML), and Robotic Process Automation (RPA) to improve process efficiency and quality along with building algorithms to analyze data as inputs into research and development or regulatory strategies.


Companies that embrace and prioritize unifying their data can meet compliance requirements and utilize trusted, curated data to unlock digital technology to improve processes and systems. Unified data can eliminate redundant processes and streamline data flows which can reduce the time to deliver life changing medicines to patients.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://regulatory-and-compliance.lifesciencesreview.com/leadership-perspective/how-to-manage-regulatory-compliance--nwid-703.html